Lonvoguran ziclumeran (lonvo-z)

In HAELO, the lonvo-z and placebo groups included 52 and 28 participants, respectively. During weeks 5–28, mean monthly attack rates were 0.26 and 2.10, corresponding to an 87% reduction with lonvo-z. The proportions without attacks were 62% and 11%. The between-group difference in change in AE-QoL score was -17.04 points. Through week 28, infusion-related reactions occurred in 32 of 52 participants (62%) receiving lonvo-z and 5 of 28 (18%) receiving placebo. No serious treatment-emergent adverse events or events of grade 3 or higher were reported in the lonvo-z group during that period.